RefleXion Debuts Next-Generation Platform with 20X Greater Sensitivity to Power SCINTIX Therapy at AAPM 2026

X2 platform detects substantially more biologic signal to enable new algorithms that potentially expand SCINTIX autonomous radiotherapy to additional tumor types

HAYWARD, Calif., July 16, 2026 — RefleXion Medical, an external beam theranostic oncology company, today announced that clinician researchers from leading institutions will present nine scientific studies featuring the new RefleXion® X2 platform at the 2026 American Association of Physicists in Medicine (AAPM) Annual Meeting, July 19–22, in Vancouver, B.C. Together these studies characterize the effect of Anchor PointTM Tracking, a new algorithm, that significantly improves the precision of SCINTIX® therapy and potentially allows it to address a wider range of tumor sizes and shapes.

AAPM 2026 marks an important milestone in the evolution of SCINTIX therapy. The new X2 platform delivers a 20-fold increase in PET sensitivity, providing substantially richer biologic data to power Anchor Point Tracking, and creating a foundation that we believe could vastly expand SCINTIX therapy eligibility.

Sean Shirvani, MD, MPH,
Chief medical officer at RefleXion.

“AAPM 2026 marks an important milestone in the evolution of SCINTIX therapy,” said Sean Shirvani, MD, MPH, chief medical officer at RefleXion. “The new X2 platform delivers a 20-fold increase in PET sensitivity, providing substantially richer biologic data to power Anchor Point Tracking, and creating a foundation that we believe could vastly expand SCINTIX therapy eligibility.

“We are grateful to our academic partners for validating the X2 platform’s performance and reinforcing its potential to treat more complex and mobile targets.”

RefleXion will also host a Key Opinion Leader luncheon on Monday, July 20, at 12:30 pm in the East Building of the Vancouver Convention Center. AAPM attendees are encouraged to register in advance to hear leading clinical experts present their research on the X2 platform and future opportunities for SCINTIX autonomous radiotherapy.

The following oral and poster presentations highlight new research showcasing SCINTIX therapy on the new X2 platform. Detailed information on all RefleXion presentations may be found here.

Oral: Evaluating Biology-guided Radiotherapy (BgRT) Dose Conformality for Complex PET-Avid Targets Under Static and Motion Conditions, Murat Surucu, PhD
Tuesday, July 21, 9:10–9:20 am in Room 109

Oral: Robustness of X2 Anchor Point Tracking to Breathing Pattern Changes During Biology-guided Radiotherapy, Murat Surucu, PhD
Wednesday, July 22, 12:09–12:16 pm in Room 220

The following poster presentations on being held in the Poster Lounge on Sunday, July 19 from 3:15–4:00 pm.

• Evaluation of a Prototype PET-Based Biology-guided Therapy (BGRT) System with Anchor Point Tracking Treatment Delivery Using Software Simulation
• Feasibility of Biology-guided Radiotherapy of Small Tumors with Extended Field-of-View PET Detectors
• PET Signal Guidance in Biology-guided Radiotherapy: Impact of Deblurring and Anchor-Point Tracking on Dosimetry
• Pre-clinical Evaluation of an Enhanced PET-Based Biology-guided Radiotherapy Platform: Phantom Experiments for Inhomogeneous Tracer-Avid Targets

Additional X2 poster presentations are featured in the Online Poster Forum on Sunday, July 19 from 7:00 am–6:00 pm.

• Dosimetric Performance for Large PET-Avid Tumors Enabled by Anchor Point Tracking and Extended PET Field-of-View
• Evaluation of OAR Sparing and Influence on Upgraded BgRT Platform
• Robustness of BgRT Delivery to Sudden Patient Shifts Evaluated in the New X2 Platform

Attendees are invited to visit RefleXion Booth #1411 throughout the meeting to discuss the X2 abstract data, see live PET demonstrations and review the treatment planning system.

About RefleXion Medical

RefleXion is a privately held external beam theranostic oncology company in Hayward, Calif., commercializing SCINTIX autonomous radiotherapy, a novel therapy that uses a single radiotracer injection to turn cancer cells into real‑time biological beacons to direct external‑beam radiotherapy. SCINTIX therapy is FDA‑cleared for FDG‑guided treatment of primary and metastatic lung and bone tumors. The RefleXion X2 platform is also cleared for conventional image‑guided radiotherapy for solid tumors anywhere in the body. Anchor Point Tracking is pending FDA 510(k) clearance and is not yet commercially available. For more information, visit www.reflexion.com.

Media Contact

contact@reflexion.com
+1-650-239-9070